PT-141 Peptide Therapy

Safety Profile of Bremelanotide Across the Clinical Development Program

Clayton AH, Kingsberg SA, Portman D et al

J Womens Health (Larchmt)Phase 3

Bremelanotide shows mostly mild-to-moderate adverse events; nausea most common reason for discontinuation.

Bremelanotide shows mostly mild-to-moderate adverse events; nausea most common reason for discontinuation

Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide

Simon JA, Kingsberg SA, Portman D et al

J Womens Health (Larchmt)Phase 3

Bremelanotide improved sexual desire and reduced distress across multiple demographic and clinical subgroups.

Bremelanotide improved sexual desire and reduced distress across multiple demographic and clinical subgroups

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Kingsberg SA, Clayton AH, Portman D et al

Obstet Gynecol · Obstet GynecolPhase 3

Bremelanotide significantly increased sexual desire and reduced distress in premenopausal women with hypoactive sexual desire disorder.

Bremelanotide significantly increased sexual desire and reduced distress in premenopausal women with hypoactive sexual desire disorder

Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder